A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
INTRODUCTION: To evaluate real-world hemoglobin A1c (HbA1c) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable se…
BACKGROUND: Glucagon-like peptide-1 receptor agonists and their analogues have emerged as effective pharmacotherapies for obesity. OBJECTIVE: To assess the short-term cost-effectiveness of subcutaneous tirzepatide, semaglutide, liraglutide, and oral…
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease and death, yet their availability in Medicaid is unc…
BACKGROUND: This meta-analysis aimed to evaluate the relation between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with type 2 diabetes mellitus (T2DM) or obesity. METHODS: A comprehensive search was con…
This systematic review and meta-analysis compared the weight loss efficacy of tirzepatide versus semaglutide in overweight and obese adults through direct comparative studies. We systematically searched PubMed, Excerpta Medica database (EMBASE), Web…
AIMS: This post hoc analysis assessed the efficacy and safety data in tirzepatide-treated Korean patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Data specifically from Korean patients treated with tirzepatide 5, 10, or 15 mg in the multic…
Type 2 diabetes mellitus (T2DM) is frequently complicated by atherosclerosis (AS), with substantial overlap in their underlying pathophysiological mechanisms, posing serious threats to patient health. Tirzepatide, a novel dual agonist of glucose-depe…
INTRODUCTION: Tirzepatide is one of the commonly used combined glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists for weight loss in recent years. There are significant advantages of these medications for…
AIMS: To characterize trends in the initiation of newer anti-obesity medications (AOMs) and determine factors associated with their use among obese/overweight populations. MATERIALS AND METHODS: This study utilized electronic health record data from…
OBJECTIVE: Interventions that combat obesity and its associated metabolic perturbations may decrease incidence and improve outcomes of endometrial cancer (EC). Potential options for weight loss include pharmacotherapeutic interventions such as tirzep…
BACKGROUND: Recent Food and Drug Administration approvals of glucagon-like peptide 1 (GLP-1) receptor agonists linked to substantial weight loss have generated interest in demand projections. However, a longitudinal analysis in a large, diverse, curr…
CONTEXT: In a clinical study, tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA), provided superior glycemic control vs the GLP-1RA semaglutide. The physiologic mechanisms are incomplete…
OBJECTIVE: This network meta-analysis evaluates the efficacy and safety of tirzepatide compared to glucagon-like peptide-1 receptor agonists (GLP-1 RA) and other weight loss drugs in the treatment of overweight and obesity. METHODS: MEDLINE, Embase,…
PURPOSE: Glucagon-like peptide 1 receptor agonists (GLP1-RA) are effective therapies in lowering glycosylated hemoglobin (HbA), providing cardioprotective benefits, and lowering weight. The use of GLP1-RA solely for weight-loss has become commonplace…
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence o…
OBJECTIVE: The study objective was to characterize subgroups of Asia-Pacific patients with type 2 diabetes who achieved different glycated hemoglobin (HbA1c) targets on tirzepatide treatment. METHODS: This was a post hoc analysis of the SURPASS AP-Co…
INTRODUCTION: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach. AREAS…
Obesity is a complex and chronic condition that presents a significant global health challenge, resulting in a wide range of health problems, such as heart disease, stroke, and diabetes, therefore diminishing the overall well-being of numerous indivi…
AIMS: To compare the efficacy and safety of tirzepatide 5, 10 and 15 mg with subcutaneous semaglutide 0.5 mg as second-line treatment for adults with type 2 diabetes mellitus, after metformin monotherapy, using adjusted indirect treatment comparisons…
Obesity and hypertension have become an international health issue, with detrimental consequences on patients. Obesity and hypertension share common pathophysiological mechanisms, such as overactivity of the renin-angiotensin-aldosterone and the symp…